Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.95 USD

2.95
429,641

+0.10 (3.51%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

by Zacks Equity Research

In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.

    What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

    by Zacks Equity Research

    Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

      What to Expect From BioMarin (BMRN) This Earnings Season?

      by Zacks Equity Research

      BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

        What's in Store for Ligand (LGND) This Earnings Season?

        by Zacks Equity Research

        Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.

          What's in the Cards for Teva (TEVA) This Earnings Season?

          by Zacks Equity Research

          Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.

            Puma, CANbridge Team Up to Commercialize Nerlynx in China

            by Zacks Equity Research

            Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

              Puma & Medison Team Up to Commercialize Nerlynx in Israel

              by Zacks Equity Research

              Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

                Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't?

                by Zacks Equity Research

                Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

                  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

                  by Zacks Equity Research

                  Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

                    Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

                    by Zacks Equity Research

                    Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.

                      Puma (PBYI) Stock Up More than 200% This Year: Here's Why

                      by Zacks Equity Research

                      Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.

                        Puma Inks License Deal to Commercialize Cancer Drug Nerlynx

                        by Zacks Equity Research

                        Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.

                          Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

                          by Zacks Equity Research

                          Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

                            Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?

                            by Zacks Equity Research

                            Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                              Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

                              by Zacks Equity Research

                              The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

                                5 Biotech Stocks Well Poised to Surpass Expectations in Q3

                                by Zacks Equity Research

                                The pharma and biotech industry has demonstrated strength

                                  Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

                                  by Zacks Equity Research

                                  Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

                                    4 Biotech Stocks That More Than Doubled This Year

                                    by Zacks Equity Research

                                    The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than doubled so far this year riding this trend.

                                      Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus

                                      by Zacks Equity Research

                                      Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.

                                        3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings

                                        by Zacks Equity Research

                                        The first half has been pretty strong for companies in the space.

                                          What's in Store for Catalyst (CPRX) This Earnings Season?

                                          by Zacks Equity Research

                                          With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.

                                            What's in Store for BioDelivery (BDSI) This Earnings Season?

                                            by Zacks Equity Research

                                            BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.

                                              What's in the Cards for Kite Pharma (KITE) in Q2 Earnings

                                              by Zacks Equity Research

                                              With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.

                                                Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?

                                                by Zacks Equity Research

                                                Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                                  Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

                                                  by Zacks Equity Research

                                                  Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.